• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA 特征可区分甲状腺乳头状癌的侵袭程度。

MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.

机构信息

Department of Surgery, Section of Endocrine Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

出版信息

Ann Surg Oncol. 2011 Jul;18(7):2035-41. doi: 10.1245/s10434-011-1733-0. Epub 2011 May 3.

DOI:10.1245/s10434-011-1733-0
PMID:21537871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4157306/
Abstract

BACKGROUND

Papillary thyroid carcinoma (PTC) has relatively indolent behavior, although some tumors recur and disseminate to distant sites. The aggressive biological behavior of PTC is difficult to predict. MicroRNAs (miRNAs) are dysregulated in various tumors types, and some of them serve as markers of poor prognosis. In this study, we evaluated miRNA expression as a marker of more aggressive behavior in PTC.

METHODS

miRNA array was used to identify a subset of differentially expressed miRNAs between aggressive and nonaggressive PTC. These miRNAs were further validated by real-time RT-PCR in a cohort of 17 PTC with local tumor recurrence or distant metastases and 15 PTC with no extrathyroidal dissemination and correlated with BRAF, RAS, and RET/PTC mutations and MET expression.

RESULTS

The miRNA array identified miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC. Significant miRNA deregulation was confirmed in the validation cohort, with upregulation of miR-146b and miR-222 and downregulation of miR-34b and miR-130b seen in aggressive PTC. Among BRAF-positive tumors, miR-146b showed strong association with aggressive PTC. MET was identified as a potential target gene for 2 downregulated miRNAs (miR-34b and miR-1), and significantly higher level of MET expression was observed in aggressive PTC.

CONCLUSIONS

We demonstrate that miR-146b, miR-222, miR-34b, miR-130b are differentially expressed in aggressive compared with nonaggressive PTC. Among BRAF-positive tumors, overexpression of miR-146b was associated with aggressive behavior, suggesting that it may further refine the prognostic importance of BRAF.

摘要

背景

甲状腺乳头状癌(PTC)的行为相对惰性,尽管有些肿瘤会复发并扩散到远处部位。PTC 的侵袭性生物学行为难以预测。microRNAs(miRNAs)在各种肿瘤类型中失调,其中一些可作为预后不良的标志物。在本研究中,我们评估了 miRNA 表达作为 PTC 侵袭性行为的标志物。

方法

使用 miRNA 芯片鉴定侵袭性和非侵袭性 PTC 之间差异表达的 miRNA 子集。通过实时 RT-PCR 在 17 例局部肿瘤复发或远处转移和 15 例无甲状腺外播散的 PTC 中进一步验证这些 miRNA,并与 BRAF、RAS 和 RET/PTC 突变和 MET 表达相关。

结果

miRNA 芯片鉴定出侵袭性 PTC 中 miR-146b、miR-221、miR-222、miR-155、miR-31 上调和 miR-1、miR-34b、miR-130b、miR-138 下调。在验证队列中证实了显著的 miRNA 失调,在侵袭性 PTC 中观察到 miR-146b 和 miR-222 的上调和 miR-34b 和 miR-130b 的下调。在 BRAF 阳性肿瘤中,miR-146b 与侵袭性 PTC 强烈相关。鉴定出 2 个下调 miRNA(miR-34b 和 miR-1)的潜在靶基因 MET,在侵袭性 PTC 中观察到 MET 表达水平显著升高。

结论

我们证明 miR-146b、miR-222、miR-34b、miR-130b 在侵袭性 PTC 中与非侵袭性 PTC 相比表达不同。在 BRAF 阳性肿瘤中,miR-146b 的过表达与侵袭性行为相关,表明其可能进一步细化 BRAF 的预后意义。

相似文献

1
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.微小 RNA 特征可区分甲状腺乳头状癌的侵袭程度。
Ann Surg Oncol. 2011 Jul;18(7):2035-41. doi: 10.1245/s10434-011-1733-0. Epub 2011 May 3.
2
Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?微 RNA 特征能否区分具有不确定恶性潜能的甲状腺肿瘤和其他分化良好的甲状腺肿瘤?
Endocr Relat Cancer. 2011 Sep 13;18(5):579-94. doi: 10.1530/ERC-10-0283. Print 2011 Oct.
3
Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.侵袭性甲状腺乳头状癌中 microRNA 和 mRNA 表达谱的综合分析。
Mol Med Rep. 2013 Nov;8(5):1353-8. doi: 10.3892/mmr.2013.1699. Epub 2013 Sep 24.
4
Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.甲状腺乳头状癌中 miRNAs 的表达及其与 BRAFV600E 突变的关系。
Eur J Endocrinol. 2013 Apr 15;168(5):675-81. doi: 10.1530/EJE-12-1029. Print 2013 May.
5
Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.miR-146b 表达的预后意义及其在甲状腺乳头状癌中的功能作用。
J Clin Endocrinol Metab. 2013 Feb;98(2):E196-205. doi: 10.1210/jc.2012-2666. Epub 2012 Dec 21.
6
Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.鉴别微小 RNA 用于管理甲状腺乳头状癌和具有甲状腺滤泡肿瘤乳头状核特征的非侵袭性肿瘤。
Thyroid. 2018 Mar;28(3):319-327. doi: 10.1089/thy.2017.0127. Epub 2018 Mar 2.
7
Association of MicroRNA Expression and BRAF Mutation with Recurrence of Thyroid Cancer.微小 RNA 表达与 BRAF 突变与甲状腺癌复发的关系。
Biomolecules. 2020 Apr 17;10(4):625. doi: 10.3390/biom10040625.
8
miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.miR-146b 在具有高危特征的成人甲状腺乳头状癌中高度表达,这些特征包括甲状腺外侵犯和 BRAF(V600E)突变。
Thyroid. 2010 May;20(5):489-94. doi: 10.1089/thy.2009.0027.
9
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.BRAF V600E突变及微小RNA表达与甲状腺乳头状癌中央区淋巴结转移的相关性:一项来自四个内分泌外科中心的前瞻性研究
Thyroid. 2016 Apr;26(4):532-42. doi: 10.1089/thy.2015.0378. Epub 2016 Mar 7.
10
MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.miR-222 和 miR-146b 是复发性甲状腺乳头状癌的组织和循环生物标志物。
Cancer. 2013 Dec 15;119(24):4358-65. doi: 10.1002/cncr.28254. Epub 2013 Oct 28.

引用本文的文献

1
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.甲状腺癌:流行病学、分类、危险因素、诊断和预后标志物以及当前的治疗策略。
Int J Mol Sci. 2025 May 28;26(11):5173. doi: 10.3390/ijms26115173.
2
The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer.基因和表观遗传修饰作为甲状腺癌诊断和预后潜在生物标志物的作用。
Front Oncol. 2024 Nov 4;14:1474267. doi: 10.3389/fonc.2024.1474267. eCollection 2024.
3
MicroRNA Profiling in Papillary Thyroid Cancer.

本文引用的文献

1
Genetic variation in microRNA networks: the implications for cancer research.miRNA 网络中的遗传变异:对癌症研究的影响。
Nat Rev Cancer. 2010 Jun;10(6):389-402. doi: 10.1038/nrc2867.
2
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.一项关于福瑞替尼(一种多靶点 c-Met 和血管内皮生长因子受体 2 抑制剂)的 I 期研究。
Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.
3
miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.
甲状腺乳头状癌中的 microRNA 谱分析。
Int J Mol Sci. 2024 Aug 29;25(17):9362. doi: 10.3390/ijms25179362.
4
Higher microRNA-221 and lower microRNA-451 expression are associated with poor prognosis in patients with thyroid papillary carcinoma.微 RNA-221 表达水平升高和微 RNA-451 表达水平降低与甲状腺乳头状癌患者的不良预后相关。
An Sist Sanit Navar. 2024 Aug 23;47(2):e1086. doi: 10.23938/ASSN.1086.
5
Biomarkers in Thyroid Cancer: Emerging Opportunities from Non-Coding RNAs and Mitochondrial Space.甲状腺癌中的生物标志物:非编码 RNA 和线粒体空间带来的新机遇。
Int J Mol Sci. 2024 Jun 18;25(12):6719. doi: 10.3390/ijms25126719.
6
Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF-associated thyroid carcinoma.靶向 miR-31 抑制 BRAF 相关甲状腺癌的肿瘤发生和去分化。
Clin Transl Med. 2024 May;14(5):e1694. doi: 10.1002/ctm2.1694.
7
MicroRNA Expression Profiling-Potential Molecular Discrimination of Papillary Thyroid Carcinoma Subtypes.微小RNA表达谱分析——甲状腺乳头状癌亚型的潜在分子鉴别
Biomedicines. 2024 Jan 9;12(1):136. doi: 10.3390/biomedicines12010136.
8
MiR-20b Tissue Expression Level Displays the Diagnostic Value in Papillary Thyroid Carcinoma.MiR-20b组织表达水平在甲状腺乳头状癌中显示出诊断价值。
Med J Islam Repub Iran. 2023 Sep 18;37:101. doi: 10.47176/mjiri.37.101. eCollection 2023.
9
New biomarkers: prospect for diagnosis and monitoring of thyroid disease.新生物标志物:甲状腺疾病的诊断和监测前景。
Front Endocrinol (Lausanne). 2023 Jul 21;14:1218320. doi: 10.3389/fendo.2023.1218320. eCollection 2023.
10
Using CRISPR/Cas9 to Edit a Thyroid Cancer Cell Line.使用 CRISPR/Cas9 编辑甲状腺癌细胞系。
Adv Exp Med Biol. 2023;1429:73-84. doi: 10.1007/978-3-031-33325-5_5.
miR-146b 在具有高危特征的成人甲状腺乳头状癌中高度表达,这些特征包括甲状腺外侵犯和 BRAF(V600E)突变。
Thyroid. 2010 May;20(5):489-94. doi: 10.1089/thy.2009.0027.
4
Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression.脊索瘤中 microRNA (miRNA) 的差异表达显示 miRNA-1 在 Met 表达中的作用。
J Orthop Res. 2010 Jun;28(6):746-52. doi: 10.1002/jor.21055.
5
Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.在甲状腺乳头癌变异型和滤泡状甲状腺肿瘤的包裹型中差异表达的 microRNA 图谱。
Br J Cancer. 2010 Jan 19;102(2):376-82. doi: 10.1038/sj.bjc.6605493. Epub 2009 Dec 22.
6
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.优化与BRAF突变相关的甲状腺乳头状癌的手术治疗
Surgery. 2009 Dec;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011.
7
Role of NF-kappaB in thyroid cancer.NF-κB 在甲状腺癌中的作用。
Mol Cell Endocrinol. 2010 May 28;321(1):29-35. doi: 10.1016/j.mce.2009.10.010. Epub 2009 Oct 30.
8
Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.对失调的微小RNA进行分析有助于鉴别低分化甲状腺癌和乳头状甲状腺癌。
Horm Metab Res. 2009 Jun;41(6):475-81. doi: 10.1055/s-0029-1215593. Epub 2009 Apr 15.
9
MicroRNA expression profiles in thyroid tumors.甲状腺肿瘤中的微小RNA表达谱
Endocr Pathol. 2009 Summer;20(2):85-91. doi: 10.1007/s12022-009-9069-z.
10
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.分子检测在改善甲状腺结节细针穿刺诊断中对突变的检测作用。
J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8. doi: 10.1210/jc.2009-0247. Epub 2009 Mar 24.